Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Pharmaceutical Preparations · Miami, FL
Our rating: Cautious
Cautious reaffirmed at $14.19, moderate conviction, November 5, 2026.
Breaks if: The Cautious call is wrong if Summit's filings or disclosures show first U.S. commercial revenue exceeding zero, or if the company submits an NDA or receives a positive pivotal-trial readout, within the next 12 months — either would demonstrate the pipeline has cleared the threshold the $11.3 billion market cap requires and would prompt a full rating review. On the upside, if the stock sustains above $20 for more than 30 consecutive trading days without a corresponding commercial or regulatory event visible in the company's disclosures, the market is pricing something the available figures do not yet show and the call must be reconsidered.
Key figures
| Market value | $8.0B |
|---|---|
| Revenue, last 12 months | n/a |
| Net income, last 12 months | −$833M |
| Free cash flow, last 12 months | −$527M |
| Price to earnings | n/a |
| Free cash flow yield | −6.6% |
| Dividend yield | 0.0% |
| Operating margin | n/a |
| Return on equity | −220.0% |
| Beta to the S&P 500 | 1.47 |
| Volatility, annualized | 199.7% |
Reported quarters
| Quarter ending | Revenue | Year on year | Earnings per share | Free cash flow |
|---|---|---|---|---|
| September 30, 2026 | n/a | n/a | $-0.26 | −$160M |
| June 30, 2026 | n/a | n/a | $-0.28 | −$142M |
| March 31, 2026 | n/a | n/a | $-0.24 | −$123M |
| December 31, 2025 | n/a | n/a | $-0.28 | −$102M |
| September 30, 2025 | n/a | n/a | $-0.31 | −$93M |
| June 30, 2025 | n/a | n/a | $-0.76 | −$67M |
| March 31, 2025 | n/a | n/a | $-0.09 | −$62M |
| December 31, 2024 | $0.00 | n/a | $-0.09 | −$49M |
Three-model forecasts for the next quarter
Written November 21, 2026, before the report. Each settles from the SEC filing.
- Diluted earnings per share are above zero: Claude 3%, Gemini 5%, Mistral 2%
- Free cash flow for the quarter is above zero: Claude 3%, Gemini 2%, Mistral 3%
38 ledger entries and 43 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.